Loading…
← CockpitCompetitor Analysis › CEVI.ST CellaVision ABOpen in the cockpit ↗

CellaVision ABCEVI.STCompetitor analysis, valuation and peers

Sweden · SEK·Health Care›Medical Specialties
Momentum leader 99
Mkt cap
$477M
US dollars, full cap
Free float
59%
of shares outstanding
$/day
$1.20M
20-day average traded
Fwd P/E
32.6×
forward earnings
ROIC−WACC
+12.1 pp
WACC 6.1%
Hurdle
-3 pp
Req g minus delivered
Next earnings
78 days
4 Feb 2027
Close · SEKSEK 203.50
1D+0.5%
1W+0.5%
1M+24.2%
3M+24.4%
6M+63.6%
YTD+29.4%
1Y+27.2%
ATR %2.7%
52w lowhigh1.7% off high

What CellaVision does

Employees: 251

CellaVision at a glance

Size CellaVision (CEVI.ST) is a Sweden Health Care company (Medical Specialties) with a market value of $477M, the 177th largest of 220 Sweden companies the cockpit tracks. Shares closed at SEK 203.50 on 18 Nov 2026.

Performance Over six months the shares gained 63.6%, against -19.0% for the median peer and +2.8% for the Sweden market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue grew 1.9% over the last twelve months (peer median +2.7%); the operating margin is 23.0% (peer median 2.7%).

Valuation It trades at 32.6× forward earnings against a peer median of 19.7× (2nd most expensive of 10).

Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -3 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 12.1 points above its cost of capital (6.1% WACC).

Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 2026CEVI.ST 167Peer median 82
Six months, rebased to 100: CellaVision against the median of its 20 peers (local-currency closes).

CellaVision financials

Reported figures in SEK; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueSEK 763MSEK 759MSEK 723MSEK 677MSEK 639M
Revenue growth—+5%+7%+6%—
Gross profitSEK 519MSEK 495MSEK 463MSEK 440MSEK 413M
EBITDASEK 222MSEK 241MSEK 219MSEK 207MSEK 202M
Net incomeSEK 138MSEK 153MSEK 141MSEK 130MSEK 118M
Free cash flowSEK 182MSEK 182MSEK 186MSEK 165MSEK 114M
Capital expenditureSEK 86.2MSEK 86.3MSEK 77.7MSEK 86.5MSEK 69.4M
Total debtSEK 49.8MSEK 25.7MSEK 26.8MSEK 64.7MSEK 102M

Quarterly statements and history in the cockpit →

CellaVision competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%-20%0%+20%300246ANGO6033093010336886060029324549603520MDXGMEDX300289468530688580002016AVR7979CEVI.ST6-month return →1-month return →
Up and to the right = strong over both horizons. CellaVision is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×40×60×6033093010336886064549603520MEDX6885807979300639CEVI.STRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. CellaVision is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%+60%0%25%50%300246603309301033688606MDXGMEDX300289688580002016603987688075300639CEVI.STGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. CellaVision is the large dot.

CellaVision competitors and peer comparison

How CellaVision compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

CellaVision against its 20 peers (data as of 18 Nov 2026)
MeasureCEVI.STPeer medianRank in peer set
1-month return+24.2%-7.1%2nd highest of 21
6-month return+63.6%-19.0%highest of 21
Distance from 52-week high-1.7%-43.4%highest of 21
Revenue growth (TTM)+1.9%+2.7%11th highest of 21
Operating margin23.0%2.7%3rd highest of 21
Forward P/E32.6×19.7×2nd most expensive of 10
Growth the price implies (Req g, 7 yrs)7.1%7.7%7th least demanding of 13
Growth delivered (Del g)+10.0%-3.6%3rd highest of 13
Hurdle (Req g minus delivered)-2.9 pp+7.7 pp3rd least demanding of 13
ROIC minus cost of capital+12.1 pp-1.9 pp2nd highest of 19
EV / EBITDA21.1×9.6×most expensive of 4
Net debt / EBITDA-0.8×-1.5×2nd most indebted of 5

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
CellaVision CEVI.STSweden$477M+64%+2%23%32.6×7.1%+10.0%
Guangdong Biolight Meditech 300246.SZChina$478M-35%+7%-8%n/a55.3%-4.7%
AngioDynamics ANGOUnited States$476M-4%+8%-6%n/an/an/a
WELL LEAD MEDICAL 603309.SSChina$473M-22%+1%15%11.9×-5.9%+7.7%
Medprin Regenerative Medical Technologies 301033.SZChina$482M-14%+23%31%22.4×4.3%+24.4%
Hangzhou Alltest Biotech 688606.SSChina$484M-20%0%13%6.9×-6.5%-4.3%
Wuhan Easy Diagnosis Biomedicine 002932.SZChina$485M-14%-9%-51%n/an/an/a
Eiken Chemical 4549.TJapan$466M-20%+4%6%24.5×n/an/a
Zhejiang Starry Pharmaceutical 603520.SSChina$491M-44%+9%3%25.8×n/an/a
MiMedx MDXGUnited States$464M-16%-23%-8%n/a10.9%+11.0%
medmix MEDX.SWSwitzerland$494M+11%-7%6%19.4×4.5%+5.0%
Beijing Leadman Biochemistry 300289.SZChina$460M-9%+46%1%n/a36.0%-6.9%
PROTEINA 468530.KSSouth Korea$460M+5%-59%-1,178%n/an/an/a
Nanjing Vishee Medical Technology 688580.SSChina$499M-43%+7%24%19.7×20.1%+4.2%
Zhejiang Orient Gene Biotech 688298.SSChina$500M-27%+18%-60%n/an/an/a
Guangdong Shirongzhaoye 002016.SZChina$453M-26%-31%3%n/a21.5%-11.7%
Shanghai Kindly Enterprises Development 603987.SSChina$452M-12%0%10%n/a-1.0%-2.8%
Assure Tech (Hangzhou) 688075.SSChina$508M-27%-9%-8%n/a30.8%-18.6%
Anteris Technologies Global AVRUnited States$508M-40%+9%-4,880%n/an/an/a
Shofu 7979.TJapan$510M+32%+9%14%13.2×n/an/a
Guangdong Hybribio Biotech 300639.SZChina$511M-18%-7%4%57.3×0.4%-13.2%

Questions

Which companies are CellaVision's closest peers?
The cockpit's peer set: Guangdong Biolight Meditech (300246.SZ), AngioDynamics (ANGO), WELL LEAD MEDICAL (603309.SS), Medprin Regenerative Medical Technologies (301033.SZ), Hangzhou Alltest Biotech (688606.SS), Wuhan Easy Diagnosis Biomedicine (002932.SZ), Eiken Chemical (4549.T), Zhejiang Starry Pharmaceutical (603520.SS).
Is CellaVision expensive compared with its peers?
On forward p/e it trades at 32.6× against a peer median of 19.7×, 2nd most expensive of 10 in its peer set. For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -3 pp: the price already allows for a slowdown.
How has CellaVision stock performed?
Over six months to 18 Nov 2026 the shares returned +63.6% against -19.0% for the median peer; over one year +27.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.